Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering

MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of its registered direct offering, priced at-the-market, of 1,954,388 shares of its common stock and 41.0412949 shares of its preferred stock. The preferred stock was offered at $100,000 per share and is immediately convertible into approximately 53,369 shares of common stock for a total of 2,190,330 shares upon conversion at a price of $1.87375 per share. The common stock was offered at $1.87375 per share. Gross offering proceeds to the company are $7.76 million.

In a concurrent private placement, the Company offered purchasers in the registered direct offering Series D warrants to purchase an aggregate of 3,108,538 shares of common stock, or 0.75 shares of common stock for each share of common stock purchased directly or issuable upon conversion of shares of preferred stock. The Series D warrants are immediately exercisable at an exercise price of $1.78 per share and expire seven years from the closing. The Series D warrants, which are callable by the company under certain circumstances, will not trade.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), acted as exclusive placement agent in connection with the offerings.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  A prospectus supplement relating to the shares of common stock and preferred stock has been filed by Cellectar with the SEC.  Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at prospectus@ladenburg.com.

About Cellectar Biosciences, Inc.
Cellectar Biosciences (CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com.

Safe Harbor Statement 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other things, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

CONTACT: 
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com

Ads

You May Also Like

SMP Pharmacy Solutions Finds $3 Million in Savings for Patients

MIAMI, Dec. 14, 2017 (GLOBE NEWSWIRE) -- SMP Pharmacy Solutions, an award-winning pharmacy, announced ...

研究人員、倖存患者、倡導者及醫生齊聚出席人數最多的世界肺癌大會,探討肺癌的研發、治療和權益倡導事務

加拿大多倫多, Sept. 26, 2018 (GLOBE NEWSWIRE) -- 患者、倖存者和倡導者偕同來自世界各地的研究人員和醫生,在國際肺癌研究協會(IASLC)於加拿大多倫多所召開的第19屆世界肺癌大會(WCLC)上共議防治肺癌的前景。大會首場新聞發佈會提到本屆破紀錄的報名參加人數(超過7,300人),審核提供患者與護理社群的工作,以加快研究步伐,評估肺癌倖存者情緒需要的相關調查資料,並強調全面基因組測序分析對患者護理的影響。 新聞發佈會由大會幾位聯合主席致辭問候開場,他們分別是醫學博士、理學學士、理學碩士Natasha B. Leighl,醫學博士、加拿大皇家內科醫學院院士、理學碩士Andrea Bezjak,以及醫學博士、加拿大皇家外科醫學院院士Gail Darling,多虧他們的不懈努力,才使得今年的大會得以在多倫多成功召開。 受致癌基因推動的患者與護理社群,為非小細胞肺癌研究創造新範例 ...